-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Intelligent Bio Solutions (INBS) Vs. Its Rivals Head-To-Head Review
Intelligent Bio Solutions (INBS) Vs. Its Rivals Head-To-Head Review
Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) is one of 223 public companies in the "Surgical & medical instruments" industry, but how does it weigh in compared to its rivals? We will compare Intelligent Bio Solutions to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
Risk & Volatility
Intelligent Bio Solutions has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions' rivals have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.
Get Intelligent Bio Solutions alerts:Profitability
This table compares Intelligent Bio Solutions and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -1,078.91% | -106.09% | -62.08% |
| Intelligent Bio Solutions Competitors | -1,355.92% | -145.04% | -26.44% |
Insider and Institutional Ownership
2.3% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 45.3% of shares of all "Surgical & medical instruments" companies are owned by institutional investors. 1.9% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 15.0% of shares of all "Surgical & medical instruments" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.Analyst Ratings
This is a summary of recent ratings and recommmendations for Intelligent Bio Solutions and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
| Intelligent Bio Solutions Competitors | 900 | 3417 | 7595 | 172 | 2.58 |
As a group, "Surgical & medical instruments" companies have a potential upside of 23.20%. Given Intelligent Bio Solutions' rivals higher probable upside, analysts plainly believe Intelligent Bio Solutions has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Intelligent Bio Solutions and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $440,000.00 | -$8.31 million | -2.12 |
| Intelligent Bio Solutions Competitors | $1.10 billion | $81.57 million | 10.59 |
Intelligent Bio Solutions' rivals have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Intelligent Bio Solutions rivals beat Intelligent Bio Solutions on 7 of the 10 factors compared.
Intelligent Bio Solutions Company Profile
(Get Rating)
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) is one of 223 public companies in the "Surgical & medical instruments" industry, but how does it weigh in compared to its rivals? We will compare Intelligent Bio Solutions to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
智能生物解決方案公司(納斯達克代碼：INBS-GET Rating)是“外科醫療器械”行業223家上市公司之一，但與競爭對手相比，它在其中的權重如何？我們將根據其估值、盈利能力、分析師建議、機構所有權、股息、風險和收益的優勢，將智能生物解決方案與類似業務進行比較。
Risk & Volatility
風險與波動性
Intelligent Bio Solutions has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions' rivals have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.
Intelligence Bio Solutions的貝塔係數為1.48，這表明其股價的波動性比標準普爾500指數高48%。相比之下，智能生物解決方案的競爭對手的貝塔係數為1.37，這表明它們的平均股價波動性比標準普爾500指數高37%。
Profitability
盈利能力
This table compares Intelligent Bio Solutions and its rivals' net margins, return on equity and return on assets.
此表比較了智能生物解決方案及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -1,078.91% | -106.09% | -62.08% |
| Intelligent Bio Solutions Competitors | -1,355.92% | -145.04% | -26.44% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 智能生物解決方案 | -1,078.91% | -106.09% | -62.08% |
| 智能生物解決方案競爭對手 | -1,355.92% | -145.04% | -26.44% |
Insider and Institutional Ownership
內部人與機構持股
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for Intelligent Bio Solutions and its rivals, as provided by MarketBeat.com.
這是對智能生物解決方案及其競爭對手最近的評級和推薦的摘要，由MarketBeat.com提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
| Intelligent Bio Solutions Competitors | 900 | 3417 | 7595 | 172 | 2.58 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 智能生物解決方案 | 0 | 0 | 0 | 0 | 不適用 |
| 智能生物解決方案競爭對手 | 900 | 3417 | 7595 | 172 | 2.58 |
As a group, "Surgical & medical instruments" companies have a potential upside of 23.20%. Given Intelligent Bio Solutions' rivals higher probable upside, analysts plainly believe Intelligent Bio Solutions has less favorable growth aspects than its rivals.
作為一個整體，“外科和醫療器械”公司有23.20%的潛在上行空間。考慮到智能生物解決方案的競爭對手更有可能上行，分析師顯然認為智能生物解決方案的增長方面不如競爭對手有利。
Earnings and Valuation
收益和估值
This table compares Intelligent Bio Solutions and its rivals top-line revenue, earnings per share and valuation.
此表比較了智能生物解決方案及其競爭對手的營收、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $440,000.00 | -$8.31 million | -2.12 |
| Intelligent Bio Solutions Competitors | $1.10 billion | $81.57 million | 10.59 |
| 總收入 | 淨收入 | 市盈率 | |
| 智能生物解決方案 | $440,000.00 | -831萬元 | -2.12 |
| 智能生物解決方案競爭對手 | 11.億美元 | 8157萬美元 | 10.59 |
Intelligent Bio Solutions' rivals have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
智能生物解決方案的競爭對手比智能生物解決方案的收入和收益更高。智能生物解決方案的市盈率低於競爭對手，這表明它目前比行業內的其他公司更實惠。
Summary
摘要
Intelligent Bio Solutions rivals beat Intelligent Bio Solutions on 7 of the 10 factors compared.
在比較的10個因素中，智能生物解決方案的競爭對手在7個方面擊敗了智能生物解決方案。
Intelligent Bio Solutions Company Profile
智能生物解決方案公司簡介
(Get Rating)
(獲取評級)
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
智能生物解決方案公司是一家生命科學公司，為患者及其初級健康從業者開發非侵入性、實時監測和診斷測試。它提供唾液葡萄糖生物傳感器，這是一種用於糖尿病治療的有機薄膜晶體管，可以測量唾液中的葡萄糖。該公司還專注於開發SARS-CoV-2生物傳感器，生物傳感器測試可作為(RNA)病毒檢測測試的補充；以及一個由生物化學、免疫學、腫瘤標誌物、激素和核酸診斷模式組成的生物傳感器平臺。該公司前身為GBS Inc.，並於2022年10月更名為Intelligence Bio Solutions Inc.。該公司成立於2016年，總部設在紐約。智能生物解決方案公司是生命科學生物傳感器診斷有限公司的子公司。
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到智能生物解決方案的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對智能生物解決方案和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧